バセドウ病市場：診断、治療、投与経路、流通チャネル、エンドユーザー別-2025-2030年の世界予測

バセドウ病市場は、2023年に5億8,385万米ドルと評価され、2024年には6億1,351万米ドルに達すると予測され、CAGR 5.42％で成長し、2030年には8億4,489万米ドルに達すると予測されています。

バセドウ病市場の範囲と定義は、甲状腺ホルモンの過剰産生を特徴とするこの自己免疫疾患の包括的な分析を包含します。その必要性は、甲状腺機能亢進症、眼疾患、皮膚症状などの症状を管理するための、その流行と効果的な診断法および治療法の必要性から生じています。最終用途には主に病院、診療所、研究機関が含まれます。市場成長を促進する主な影響要因としては、罹患率の増加、高度な診断能力、自己免疫疾患への注目の高まりなどが挙げられます。生物学的製剤や免疫療法などの新規治療薬の開発、早期診断のためのAIの活用など、ビジネスチャンスは豊富にあります。個別化医療や患者中心のケアモデルへの投資は、特に医療費の増加に伴い、成長を大きく促進する可能性があります。しかし、治療費の高さ、現行薬の副作用、自己免疫疾患の複雑さなどの限界は依然として残っており、普及の妨げになる可能性があります。さらに、規制上のハードルや、有効性と安全性を証明するための大規模な臨床試験の必要性といった課題も、依然として重要な問題です。バセドウ病の理解と治療を強化するためには、分子レベルの研究に焦点を当て、遺伝的素因や環境的誘因を探る必要があります。市場参入企業は、新規製剤や診断ツールの研究開発を推進するため、研究機関との連携を優先すべきです。バセドウ病市場は、医療政策の変化と技術の進歩に支えられながら、緩やかながらも安定した成長を続けています。企業は規制の変化を常に把握し、バイオシミラーのようなイノベーションを通じて治療費削減に取り組む必要があります。戦略的パートナーシップ、製品の多様化、新興国への市場参入は、市場の潜在力を高める可能性があります。さらに、患者に焦点を当てたアプローチと治療選択肢に関する教育により、患者のアドヒアランスと転帰を向上させ、ブランドの信頼とロイヤルティを高めることで市場のリーダーを確立することができます。

市場力学：急速に進化するバセドウ病市場の主要市場インサイトを公開

バセドウ病市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の自己免疫疾患の有病率の上昇
  • 政府主導による国民の意識の高まり
  • 個別化医療に対する需要の高まり
• 市場抑制要因
  • 高度な治療法および診断法に伴う高コスト
• 市場機会
  • 先進治療薬の研究開発活動の活発化
  • 研究機関とバイオテクノロジー企業との協力関係の構築
• 市場の課題
  • 厳しい規制環境と複雑な承認手続き

ポーターのファイブフォース：バセドウ病市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：バセドウ病市場における外部からの影響の把握

外部マクロ環境要因は、バセドウ病市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析バセドウ病市場における競合情勢の把握

バセドウ病市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスバセドウ病市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、バセドウ病市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨バセドウ病市場における成功への道筋を描く

バセドウ病市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 自己免疫疾患の有病率が世界的に上昇
    • 政府の取り組みの増加に伴い国民の意識が高まっている
    • パーソナライズ医療の需要の高まり
  • 抑制要因
    • 高度な治療と診断に伴う高コスト
  • 機会
    • 先進的治療法の継続的な研究開発活動
    • 調査機関とバイオテクノロジー企業間の新たな連携
  • 課題
    • 厳格な規制環境と複雑な承認手続き
• 市場セグメンテーション分析
  • 治療：バセドウ病治療における放射性ヨウ素療法の普及
  • 投与経路：バセドウ病の急性期治療における静脈内投与の適用が拡大している
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 バセドウ病市場診断別

• 血液検査
  • 無料のT4およびT3レベル
  • 甲状腺刺激ホルモン（TSH）レベル
  • TSH受容体抗体（TSH-RAb）
• 画像検査
  • CTまたはMRIスキャン
  • 放射性ヨウ素の摂取
  • 甲状腺超音波検査
• 身体検査

第7章 バセドウ病市場治療別

• 補助治療
• 医薬品
  • 抗甲状腺薬
  • ベータ遮断薬
    • アテノロール
    • プロプラノロール
• 放射性ヨウ素療法
• 手術

第8章 バセドウ病市場：投与経路別

• 静脈内
• オーラル
• 外科的介入

第9章 バセドウ病市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局
• 専門薬局

第10章 バセドウ病市場：エンドユーザー別

• ヘルスケア提供者
• 病院・クリニック
• 個々の患者

第11章 南北アメリカのバセドウ病市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域のバセドウ病市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのバセドウ病市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • IBSA USAは、ゴルファーのアザハラ・ムニョスとの提携を更新し、比類のない柔軟性と利便性を提供するFDA承認の甲状腺機能低下症治療Tirosint-SOLの認知度を高めます。
  • イノベント・バイオロジクスの抗IGF-1R抗体IBI311が中国で甲状腺眼症の優先審査を獲得、臨床上の大きな進歩と世界展開を支援
  • アムジェン社、甲状腺眼症治療薬テプロツムマブのEU承認によりバセドウ病治療の進歩に着手、長期市場拡大と患者ケア強化を計画
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AbbVie Inc.
• AdvanceCor GmbH
• Amgen Inc.
• Bayer AG
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GSK plc
• Immunovant, Inc.
• Jubilant Pharma Holdings Inc.
• Lannett Company, Inc.
• Lupin Limited
• Medtronic PLC
• Merck KGaA
• Novartis AG
• Omeros Corp
• OSE Immunotherapeutics SA
• Protheragen Inc
• RLC Labs, Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Thermo Fisher Scientific Inc.
• Viatris Inc.
• Zenas BioPharma, Inc.

LIST OF FIGURES

• FIGURE 1. GRAVES DISEASE MARKET RESEARCH PROCESS
• FIGURE 2. GRAVES DISEASE MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GRAVES DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GRAVES DISEASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL GRAVES DISEASE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL GRAVES DISEASE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES GRAVES DISEASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES GRAVES DISEASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. GRAVES DISEASE MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. GRAVES DISEASE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GRAVES DISEASE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GRAVES DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GRAVES DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GRAVES DISEASE MARKET DYNAMICS
• TABLE 7. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GRAVES DISEASE MARKET SIZE, BY CT OR MRI SCANS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADJUNCTIVE TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTI-THYROID DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL GRAVES DISEASE MARKET SIZE, BY ATENOLOL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL GRAVES DISEASE MARKET SIZE, BY PROPRANOLOL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL GRAVES DISEASE MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL GRAVES DISEASE MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL GRAVES DISEASE MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL GRAVES DISEASE MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL GRAVES DISEASE MARKET SIZE, BY INDIVIDUAL PATIENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 68. BRAZIL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 69. BRAZIL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 71. CANADA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 72. CANADA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 73. CANADA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 74. CANADA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 75. CANADA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 76. CANADA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 77. CANADA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. CANADA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. CANADA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 80. MEXICO GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 81. MEXICO GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 82. MEXICO GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 83. MEXICO GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 84. MEXICO GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 85. MEXICO GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 86. MEXICO GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 87. MEXICO GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. MEXICO GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. UNITED STATES GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 90. UNITED STATES GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 91. UNITED STATES GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 92. UNITED STATES GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 93. UNITED STATES GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 94. UNITED STATES GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 95. UNITED STATES GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. UNITED STATES GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. UNITED STATES GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. UNITED STATES GRAVES DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 99. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 100. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 101. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 102. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 103. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 104. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 105. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 106. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 108. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 109. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 110. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 111. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 112. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 113. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 114. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 115. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 116. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 117. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 118. CHINA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 119. CHINA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 120. CHINA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 121. CHINA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 122. CHINA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 123. CHINA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 124. CHINA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. CHINA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. CHINA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 127. INDIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 128. INDIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 129. INDIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 130. INDIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 131. INDIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 132. INDIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 133. INDIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 134. INDIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 135. INDIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 136. INDONESIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 137. INDONESIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 138. INDONESIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 139. INDONESIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 140. INDONESIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 141. INDONESIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 142. INDONESIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. INDONESIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. INDONESIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 145. JAPAN GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 146. JAPAN GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 147. JAPAN GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 148. JAPAN GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 149. JAPAN GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 150. JAPAN GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 151. JAPAN GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 152. JAPAN GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 153. JAPAN GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 154. MALAYSIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 155. MALAYSIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 156. MALAYSIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 157. MALAYSIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 158. MALAYSIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 159. MALAYSIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 160. MALAYSIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 161. MALAYSIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 162. MALAYSIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 163. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 164. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 165. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 166. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 167. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 168. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 169. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 170. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 171. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 172. SINGAPORE GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 173. SINGAPORE GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 174. SINGAPORE GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 175. SINGAPORE GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 176. SINGAPORE GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 177. SINGAPORE GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 178. SINGAPORE GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. SINGAPORE GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 180. SINGAPORE GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 181. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 182. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 183. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 184. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 185. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 186. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 187. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 188. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 189. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 190. TAIWAN GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 191. TAIWAN GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 192. TAIWAN GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 193. TAIWAN GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 194. TAIWAN GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 195. TAIWAN GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 196. TAIWAN GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 197. TAIWAN GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 198. TAIWAN GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 199. THAILAND GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 200. THAILAND GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 201. THAILAND GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 202. THAILAND GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 203. THAILAND GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 204. THAILAND GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 205. THAILAND GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 206. THAILAND GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 207. THAILAND GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 208. VIETNAM GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 209. VIETNAM GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 210. VIETNAM GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 211. VIETNAM GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 212. VIETNAM GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 213. VIETNAM GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 214. VIETNAM GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 215. VIETNAM GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 216. VIETNAM GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 223. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 224. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 225. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 226. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 227. DENMARK GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 228. DENMARK GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 229. DENMARK GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 230. DENMARK GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 231. DENMARK GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 232. DENMARK GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 233. DENMARK GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 234. DENMARK GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 235. DENMARK GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 236. EGYPT GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 237. EGYPT GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 238. EGYPT GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 239. EGYPT GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 240. EGYPT GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 241. EGYPT GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 242. EGYPT GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 243. EGYPT GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 244. EGYPT GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 245. FINLAND GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 246. FINLAND GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 247. FINLAND GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 248. FINLAND GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 249. FINLAND GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 250. FINLAND GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 251. FINLAND GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 252. FINLAND GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 253. FINLAND GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 254. FRANCE GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 255. FRANCE GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 256. FRANCE GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 257. FRANCE GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 258. FRANCE GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 259. FRANCE GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 260. FRANCE GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 261. FRANCE GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 262. FRANCE GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 263. GERMANY GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 264. GERMANY GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 265. GERMANY GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 266. GERMANY GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 267. GERMANY GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 268. GERMANY GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 269. GERMANY GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 270. GERMANY GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 271. GERMANY GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 272. ISRAEL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 273. ISRAEL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 274. ISRAEL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 275. ISRAEL GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 276. ISRAEL GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 277. ISRAEL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 278. ISRAEL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 279. ISRAEL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 280. ISRAEL GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 281. ITALY GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 282. ITALY GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 283. ITALY GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 284. ITALY GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 285. ITALY GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 286. ITALY GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 287. ITALY GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 288. ITALY GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 289. ITALY GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 290. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 291. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 292. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 293. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 294. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 295. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 296. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 297. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 298. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 299. NIGERIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 300. NIGERIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 301. NIGERIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 302. NIGERIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 303. NIGERIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 304. NIGERIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 305. NIGERIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 306. NIGERIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 307. NIGERIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 308. NORWAY GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 309. NORWAY GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 310. NORWAY GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 311. NORWAY GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 312. NORWAY GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 313. NORWAY GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 314. NORWAY GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 315. NORWAY GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 316. NORWAY GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 317. POLAND GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 318. POLAND GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 319. POLAND GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 320. POLAND GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 321. POLAND GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 322. POLAND GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 323. POLAND GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 324. POLAND GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 325. POLAND GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 326. QATAR GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 327. QATAR GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 328. QATAR GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 329. QATAR GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 330. QATAR GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 331. QATAR GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 332. QATAR GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 333. QATAR GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 334. QATAR GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 335. RUSSIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 336. RUSSIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 337. RUSSIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 338. RUSSIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 339. RUSSIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 340. RUSSIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 341. RUSSIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 342. RUSSIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 343. RUSSIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 344. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 345. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 346. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 347. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 348. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 349. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 350. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 351. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 352. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 353. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 354. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
• TABLE 355. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 356. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 357. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 358. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 359. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 360. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 361. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 362. SPAIN GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 363. SPAIN

The Graves Disease Market was valued at USD 583.85 million in 2023, expected to reach USD 613.51 million in 2024, and is projected to grow at a CAGR of 5.42%, to USD 844.89 million by 2030.

The scope and definition of the Graves' Disease market encompass a comprehensive analysis of this autoimmune disorder characterized by overproduction of thyroid hormones. The necessity stems from its prevalence and the need for effective diagnostics and therapeutics to manage symptoms like hyperthyroidism, eye diseases, and skin conditions. The application involves pharmaceuticals, diagnostics, and personalized medicine, while the end-use scope primarily includes hospitals, clinics, and research institutes. Key influencing factors driving market growth include increasing incidence rates, advanced diagnostic capabilities, and a growing focus on autoimmune diseases. Opportunities abound in developing novel therapeutics, such as biologics and immunotherapies, and leveraging AI for early diagnosis. Investing in personalized medicine and patient-centric care models can significantly drive growth, especially with rising healthcare spending. However, limitations persist, like the high cost of treatment, side effects of current medications, and the complexity of autoimmune conditions, potentially hindering widespread adoption. Moreover, challenges such as regulatory hurdles and the need for extensive clinical trials to prove efficacy and safety remain pivotal issues. Innovation should focus on molecular-level research, exploring genetic predispositions and environmental triggers to enhance understanding and treatment of Graves' Disease. Market participants should prioritize collaborations with research institutions to drive R&D in novel drug formulations and diagnostic tools. The nature of the market leans towards moderate but consistent growth, tethered by healthcare policy changes and technological advancements. Companies should stay abreast of regulatory shifts and work towards reducing treatment costs through innovations like biosimilars. Strategic partnerships, product diversification, and market entry in emerging economies could ramp up market potential. Additionally, a patient-focused approach and education about treatment options could foster better patient adherence and outcomes, establishing market leaders through enhanced brand trust and loyalty.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Graves Disease Market

The Graves Disease Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of autoimmune disorders globally
  • Increasing awareness among population with rising government initiatives
  • Growing demand for personalized medecine
• Market Restraints
  • High cost associated with advanced therapeutics and diagnostics
• Market Opportunities
  • Ongoing research and development activities for advanced therapies
  • Emerging collaboration between research institutes and biotech firms
• Market Challenges
  • Stringent regulatory environments and complex approval procedures

Porter's Five Forces: A Strategic Tool for Navigating the Graves Disease Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Graves Disease Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Graves Disease Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Graves Disease Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Graves Disease Market

A detailed market share analysis in the Graves Disease Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Graves Disease Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Graves Disease Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Graves Disease Market

A strategic analysis of the Graves Disease Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Graves Disease Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., AdvanceCor GmbH, Amgen Inc., Bayer AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GSK plc, Immunovant, Inc., Jubilant Pharma Holdings Inc., Lannett Company, Inc., Lupin Limited, Medtronic PLC, Merck KGaA, Novartis AG, Omeros Corp, OSE Immunotherapeutics SA, Protheragen Inc, RLC Labs, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., Viatris Inc., and Zenas BioPharma, Inc..

Market Segmentation & Coverage

This research report categorizes the Graves Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Diagnosis, market is studied across Blood Tests, Imaging Tests, and Physical Examination. The Blood Tests is further studied across Free T4 & T3 Levels, Thyroid-Stimulating Hormone (TSH) Levels, and TSH Receptor Antibodies (TSH-RAb). The Imaging Tests is further studied across CT or MRI Scans, Radioactive Iodine Uptake, and Thyroid Ultrasound.
• Based on Treatment, market is studied across Adjunctive Treatments, Medications, Radioactive Iodine Therapy, and Surgery. The Medications is further studied across Anti-thyroid Drugs and Beta-Blockers. The Beta-Blockers is further studied across Atenolol and Propranolol.
• Based on Route of Administration, market is studied across Intravenous, Oral, and Surgical Intervention.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Specialty Pharmacies.
• Based on End User, market is studied across Healthcare Providers, Hospitals & Clinics, and Individual Patients.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of autoimmune disorders globally
    • 5.1.1.2. Increasing awareness among population with rising government initiatives
    • 5.1.1.3. Growing demand for personalized medecine
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with advanced therapeutics and diagnostics
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing research and development activities for advanced therapies
    • 5.1.3.2. Emerging collaboration between research institutes and biotech firms
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory environments and complex approval procedures
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment: Proliferation of radioactive iodine therapy for Graves' disease treatment
  • 5.2.2. Route of Administration: Growing application of intravenous administration for acute management of Graves' disease
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Graves Disease Market, by Diagnosis

• 6.1. Introduction
• 6.2. Blood Tests
  • 6.2.1. Free T4 & T3 Levels
  • 6.2.2. Thyroid-Stimulating Hormone (TSH) Levels
  • 6.2.3. TSH Receptor Antibodies (TSH-RAb)
• 6.3. Imaging Tests
  • 6.3.1. CT or MRI Scans
  • 6.3.2. Radioactive Iodine Uptake
  • 6.3.3. Thyroid Ultrasound
• 6.4. Physical Examination

7. Graves Disease Market, by Treatment

• 7.1. Introduction
• 7.2. Adjunctive Treatments
• 7.3. Medications
  • 7.3.1. Anti-thyroid Drugs
  • 7.3.2. Beta-Blockers
    • 7.3.2.1. Atenolol
    • 7.3.2.2. Propranolol
• 7.4. Radioactive Iodine Therapy
• 7.5. Surgery

8. Graves Disease Market, by Route of Administration

• 8.1. Introduction
• 8.2. Intravenous
• 8.3. Oral
• 8.4. Surgical Intervention

9. Graves Disease Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacies
• 9.3. Online Pharmacies
• 9.4. Retail Pharmacies
• 9.5. Specialty Pharmacies

10. Graves Disease Market, by End User

• 10.1. Introduction
• 10.2. Healthcare Providers
• 10.3. Hospitals & Clinics
• 10.4. Individual Patients

11. Americas Graves Disease Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Graves Disease Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Graves Disease Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. IBSA USA Renews Alliance with Golfer Azahara Munoz to Boost Awareness for FDA-Approved Tirosint-SOL, the Hypothyroidism Treatment Offering Unmatched Flexibility and Convenience
  • 14.3.2. Innovent Biologics' Advancement Anti-IGF-1R Antibody IBI311 Secures Priority Review for Thyroid Eye Disease in China, Supporting Major Clinical Advances and Global Expansion
  • 14.3.3. Amgen Moves to Advance Graves' Disease Treatment with EU Approval of Teprotumumab for Thyroid Eye Disease; Plans for Long-Term Market Expansion and Patient Care Enhancements
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. AdvanceCor GmbH
• 4. Amgen Inc.
• 5. Bayer AG
• 6. Eli Lilly and Company
• 7. F. Hoffmann-La Roche Ltd.
• 8. GSK plc
• 9. Immunovant, Inc.
• 10. Jubilant Pharma Holdings Inc.
• 11. Lannett Company, Inc.
• 12. Lupin Limited
• 13. Medtronic PLC
• 14. Merck KGaA
• 15. Novartis AG
• 16. Omeros Corp
• 17. OSE Immunotherapeutics SA
• 18. Protheragen Inc
• 19. RLC Labs, Inc.
• 20. Sanofi S.A.
• 21. Teva Pharmaceutical Industries Ltd.
• 22. Thermo Fisher Scientific Inc.
• 23. Viatris Inc.
• 24. Zenas BioPharma, Inc.